Amgen Inc. has an expansion plan and China is a part of it. On 31 October, the major US biotech announced the acquisition of a 20.5% stake in Beijing-based BeiGene Ltd. for $2.7bn in cash, paying a 36% premium over Nasdaq-listed BeiGene’s 30-day volume-weighted share price.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?